William Blum

机构：Emory University, Cancer Institute (WIA) · ORCID：0000-0003-0111-7465

发表论文 414 篇 · 总被引 13443 次 · h-index 59

代表论文

• Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1 -Mutated or KMT2A -Rearranged AML (2025 · Journal of Clinical Oncology · 被引 36)
• Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial (2025 · Journal of Hematology & Oncology · 被引 15)
• Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia (2025 · Leukemia · 被引 10)
• A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia (2025 · Blood Neoplasia · 被引 10)
• Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial (2025 · Blood Cancer Journal · 被引 10)
• Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax:  a multinational retrospective cohort study (2025 · Blood · 被引 6)